Efficacy, safety and tolerability of the CCR1 antagonist BAY 86-5047 for the treatment of endometriosis-associated pelvic pain: a randomized controlled trial.
Saved in:
| Title: | Efficacy, safety and tolerability of the CCR1 antagonist BAY 86-5047 for the treatment of endometriosis-associated pelvic pain: a randomized controlled trial. |
|---|---|
| Authors: | Trummer D; R&D Statistics, Bayer Pharma AG, Global Development, Berlin, Germany., Walzer A; Global Clinical Development, Bayer Pharma AG, Global Development, Berlin, Germany., Groettrup-Wolfers E; Global Pharmacovigilance, Bayer Pharma AG, Global Development, Berlin, Germany., Schmitz H; Global Clinical Development, Bayer Pharma AG, Global Development, Berlin, Germany. |
| Source: | Acta obstetricia et gynecologica Scandinavica [Acta Obstet Gynecol Scand] 2017 Jun; Vol. 96 (6), pp. 694-701. Date of Electronic Publication: 2017 Mar 16. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0370343 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0412 (Electronic) Linking ISSN: 00016349 NLM ISO Abbreviation: Acta Obstet Gynecol Scand Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
